Objective: Adverse effects of obesity have been linked to inflammation in various tissues, but studies on placental inflammation and obesity have demonstrated conflicting findings. We sought to investigate the influence of pregravid obesity and fetal sex on placental histopathology while controlling for diabetes and hypertension. Methods: Placental histopathology focusing on inflammatory markers of a cohort of normal weight (BMI ¼ 20e24.9) and obese (BMI ! 30) patients was characterized. Demographic, obstetric and neonatal variables were assessed. Results: 192 normal and 231 obese women were included. Placental characteristics associated with obesity and fetal sex independent of diabetes and hypertension were placental disc weight >90 th percentile, decreased placental efficiency, chronic villitis (CV), fetal thrombosis, and normoblastemia. Additionally, female fetuses of obese mothers had higher rates of CV and fetal thrombosis. Increasing BMI increased the risk of normoblastemia and CV. The final grade and extent of CV was significantly associated with obesity and BMI, but not fetal gender. Finally, CV was less common in large-for-gestation placentas. Conclusions: Maternal obesity results in placental overgrowth and fetal hypoxia as manifested by normoblastemia; it is also associated with an increased incidence of CV and fetal thrombosis, both more prevalent in female placentas. We have shown for the first time that the effect of maternal obesity on placental inflammation is independent of diabetes and hypertension, but significantly affected by fetal sex. Our data also point to the intriguing possibility that CV serves to normalize placental size, and potentially fetal growth, in the setting of maternal obesity.
Introduction
Over the last decade, studies have established that maternal obesity increases morbidity and mortality for the maternalefetal dyad [1, 2] . Maternal morbidities include gestational diabetes mellitus (GDM), gestational hypertension (GHTN), preeclampsia/ eclampsia [1, 3] , labor dystocia [4] , operative and Cesarean delivery, and postpartum hemorrhage [5] . Offspring of obese mothers are at a higher risk of macrosomia (birth weight > 4 kg) as well as intrauterine fetal demise (IUFD) [6, 7] . Furthermore, these neonates are at increased risk of obesity and metabolic disease later in their own adult life [8, 9] .
Several studies support the association between pregravid obesity and placental pathology. These include an association with increased placental weight and reduced efficiency, the latter measured as a ratio of birthweight to placental weight [10, 11] . Likewise, inflammation in the form of chorioamnionitis has been documented in placentas of obese women [11, 12] ; this lesion is most often a mixed infiltrate composed of neutrophils and lymphocytes and is thought to be maternal in origin, although it can be accompanied by a fetal response [13] . This is not surprising given the increased risk of labor dystocia and prolonged ruptured membranes [4] .
However, the more common inflammatory cell type seen infiltrating tissues in the setting of obesity is the macrophage [14] , a cell type often seen in a placental disc lesion called "chronic villitis" [13, 15] . Chronic villitis (CV) is defined by the presence of a mixture of macrophages and lymphocytesdmostly T cellsdinfiltrating chorionic villi [15] . While some are secondary to infection (i.e. with TORCH-related microorganisms such as CMV), the majority cannot be linked to any pathogen and are therefore thought to represent a transplantation rejection reaction, otherwise known as villitis of unknown etiology or VUE [13, 15] . Where this lesion involves large areas of the placenta, it has been associated with intrauterine growth restriction and recurrent pregnancy loss [13, 15] . In addition, and particularly when associated with obliterative fetal vascular lesions ("obliterative fetal vasculopathy"), CV is also known to be a risk factor for neonatal encephalopathy and cerebral palsy [15e17] .
Evaluations of CV in the setting of maternal obesity have shown conflicting results; however, these studies have been relatively small in sample size (<50 per group): Challier et al. noted an increase in the number of resident macrophages in the placentas of obese women [18] , while Roberts et al. were unable to see major differences in immune cell infiltration within the chorionic villi [19] , instead, only noting increased expression of pro-inflammatory cytokines in such placentas. Larger studies have not addressed this question [11] .
Pregnancy outcomes and placental pathology are also dependent on fetal sex [20] . Male neonates are often larger than females and have an increased risk of preterm birth and stillbirth, while pregnancies with female fetuses tend to be at a higher risk of preterm preeclampsia [21e23] . Relatively few studies have evaluated sex-related differences in placental pathology. Walker et al. reported placentas of male fetuses having significantly higher rates of velamentous insertion of umbilical cord and chronic deciduitis, and lower rates of villous infarction compared to those of female fetuses [24] . A relationship with fetal sex has not been described for either CV or fetal thrombosis.
This study aimed to evaluate placental pathology in the setting of pregravid obesity in patients delivering at or near term, with a focus on CV, as this is the main lesion involving infiltration of macrophages in the placental villi. Given the links between maternal obesity with diabetes and hypertensive diseases of pregnancy, as well as the association between fetal sex and pregnancy outcomes, this study explored the influence of these variables on placental pathology in the setting of maternal obesity. The hypothesis was that maternal obesity is linked to specific pathologic findings of the placenta, which differ based on fetal sex.
Materials and methods
The study, approved by the Human Research Protections Program Committee of the University of California San Diego (UCSD) Institutional Review Board, is part of a Perinatal Biospecimen Banking study, where both low-and high-risk pregnant patients are consented, and both clinical data as well as various biospecimens, including placental tissue, are collected. The subjects for this study were selected from amongst this study population based on the following criteria: delivery of a singleton, live-born infant at or after 35 weeks gestational age between January 1, 2010 to April 30, 2013 ; and documented maternal pregravid or early pregnancy weight (obtained prior to 14 weeks). Maternal demographic, anthropometric, and obstetric data, as well as neonatal outcomes data were abstracted from the electronic medical record. Placental examination, including gross and histologic examinations, were performed either through the hospital (for those with a clinical indication for placental exam) or through the research core (for those placentas without such indications). [25] . Preeclampsia or preeclampsia with severe features was defined based on ACOG criteria [25] .
Maternal data

Neonatal data
Neonatal gender, birthweight (grams) and the APGAR scores at 1 and 5 min were recorded. Birthweight percentile (BW%) was adjusted for gender and gestational age based on the 1999e2000 US Natality Datasets [26, 27] ; category of growth was classified by the following defined as follows: small for gestational age (SGA) as birth weight of 10th percentile, normal for gestational age as birth weight between 11th and 89th percentile, and large for gestational age (LGA) as birth weight ! 90 th percentile. Macrosomia was defined as birth weight greater than 4000 g [6, 7, 28, 29] .
Placental histopathology data
Placental examination was performed by a single pathologist (MMP) using standard protocols [13] .
Gross examination
Size, weight, and lesions of the placental disc were recorded. Specifically, the weight of the unfixed disc was measured without attached cord and membranes. Placental weight percentile was adjusted for gestational age [30] , and designated as "large" if it was !90th percentile for gestation. Placental efficiency was defined by the ratio of fetal to placental weight at delivery.
Fetal membrane (color and insertion) and umbilical cord (length, insertion site, and lesions) were also evaluated. "Umbilical cord abnormality" was defined based on factors associated with umbilical cord obstruction, and included abnormally long cord, hypertwisting (>3 twists per 10 cm), or the presence of true knot(s) [31] .
For each placenta, the following sections were examined histologically: one section each of umbilical cord and membrane roll; any disc lesions; and two full-thickness sections of grossly-normal placental disc. All these sections were processed, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E) using standard protocols.
Histologic examination
Each subject had a detailed placental pathology examination by a single pathologist (MMP). The pathologist was blinded to fetalsex and maternal BMI. Only minimal obstetric information was recorded in the pathology request form, including gestational age and indication for placental examination (i.e. diabetes, preeclampsia, intrauterine growth restriction). The presence or absence of the histopathologic findings listed in Table 1 was documented. These findings were defined by previouslyestablished criteria [13] .
Placentas with CV were graded jointly by one board-certified anatomic pathologist (MMP) and one pathologist-in-training (XL), blinded to clinical information, using a modified version of the Redline method [15] , where a focus of CV was classified as low grade (<10 inflamed villi per focus), high grade (>10 inflamed villi per focus but each focus still fits into a 10x field), or diffuse (focus of villitis fills up more than a 10x field). For placentas with only low and/or high grade foci, the number of CV foci were counted; then the following formula was used to determine the final grade of the entire case:
Each case was graded as low grade (grade ¼ 1) if the above value was <1.5 and high grade (grade ¼ 2) if the value was >1.5; if even one focus of diffuse CV was identified, it was considered diffuse (grade ¼ 3).
For evaluating extent of CV, the numerator of the above formula was used [(Number low grade foci Â 1.0) þ (number of high grade foci Â 2.0)]. Among those with only low and/or high grade CV, the highest score was 11; therefore, all "diffuse" cases were arbitrarily assigned an "extent" score of 12.
A total of 20 cases (5 from each of 4 categories: normal vs. obese, with and without CV) were also evaluated by immunohistochemistry for T-cells (CD3; rabbit anti-CD3 antibody, clone #EP449E, Abcam) and macrophages (CD68; mouse anti-CD68 antibody, clone #KP1, Dako), using a Ventana automated stainer.
Statistical analysis
Statistical analysis was performed using SPSS software (SPSS release 21.0, Chicago, IL, USA). Bivariate analyses were performed to examine maternal and perinatal differences between normal and obese groups. Student's t-test and Chi-square were used for analyses of continuous and categorical variables, respectively.
Goodman's Gamma test for ordinal variables was performed for birth weight percentile classifications. The same approach was applied to evaluate maternal and perinatal differences between CV, fetal thrombosis, normoblastemia, and large placental disc groups.
Placental pathologic outcomes, including gross and histologic findings were compared between maternal weight (lean/obese) and fetal sex groups in bivariate and multivariate analyses. Placental findings (placental large disc, normoblastemia, CV, and fetal thrombosis) were adjusted for maternal, placental and gender covariates in the multivariate analysis. Only variables with a p value of <0.2 were considered candidate covariates. The choice of relevant covariates for adjustment was done by backward model selection. The candidate covariates were fetal sex, parity, maternal obesity, maternal hypertensive disorder, preterm delivery, and placental findings (large disc weight, abnormal umbilical cord, CV, fetal thrombosis, intervillous thrombus, decidual vasculopathy, infarcts, normoblastemia, fetal vasculitis, and retroplacental hematoma). Finally, multivariate logistic regression models were used to compare the proportion of placental findings that were associated with maternal obesity and fetal sex. Adjusted odd ratios (aOR) and 95% confidence intervals (95% CI) were reported. All statistical tests were two-sided, with p-values less than 0.05 considered statistically significant.
Results
Maternal and perinatal characteristics in relation to maternal BMI
Four hundred and twenty-three women were included in the study (192 normal weight and 231 obese). Maternal and fetal characteristics are summarized in Table 2 . Mean maternal age and mode of delivery were similar between groups. Obese women were more likely to be Hispanic, multiparous, diabetic, and hypertensive, with a lower gestational age at delivery. Fetal gender and APGAR scores were not different between the two groups. As anticipated, birthweight demonstrated a significant positive association with maternal obesity.
Placental findings by maternal characteristics and fetal sex
The mean disc weight of placentas from obese patients was 44 g greater than normal-weight patients (Table 3) . Other significant placental pathology associated with obesity included CV, normoblastemia, and decidual vasculopathy (Table 3) . Interestingly, CV was more common in female placentas, but only in the setting of maternal obesity (p ¼ 0.018). In the bivariate analysis, decidual vasculopathy was associated with obesity, but multivariate analysis After controlling for specific maternal and placental characteristics, as well as fetal sex, large placental disc weight was significantly associated with maternal obesity (Table 5) . Parity was shown to have a modest influence on placental disc weight (Para 0 ¼ 456.0 ± 122.6 g; Para 1e4 ¼ 497.3 ± 138.4 g; Para ! 5 ¼ 483.0 ± 97.7 g; p ¼ 0.006); however after controlling for maternal BMI, this association was no longer statistically significant. The only placental pathologies associated with parity included fetal vasculitis (p ¼ 0.017), maternal infarcts (p ¼ 0.019), and a trend in chorioamnionitis (p ¼ 0.052). Parity did not influence any other placental histopathologic findings. The presence of normoblastemia was associated with obesity, gross umbilical cord abnormalities, and decidual vasculopathy. These associations were not found with maternal diabetes. Inflammation in the placental disc (CV) was also more common in the obese group, independent of maternal diabetes and hypertensive disease (Table 5) . We further stratified maternal obesity by pre-pregnancy BMI category, including normal weight (20e24.9 kg/m 2 ), class I obesity Two placental lesions were found to be associated with fetal sex: fetal thrombosis was more common in female, and villous edema was more common in the male placentas (Table 5 ). Fetal thrombosis was also associated with both large placental disc and CV, while villous edema was also associated with preterm placentas (Table 5) .
The association of CV with a decreased risk of large placental disc nearly reached significance (aOR of 0.49, with CI [0.24, 1.02]). This association persisted when the cases were stratified based on maternal obesity: 14.9% of obese women with CV had large placental discs as opposed to 25.7% of obese women without CV (aOR of 0.51, with CI [0.22, 1.06]).
When evaluating CV with respect to grade and extent, almost half of the CV (28/57) in obese placentas, but only 14% of CV (4/28) in lean placentas, demonstrated a diffuse distribution (X 2 ¼ 9.71, p < 0.01). Using logistic regression analysis, the final grade (low, high, diffuse) and extent (sum of foci with villitis) of CV was significantly associated with obesity and BMI (p ¼ 0.001), but not fetal gender. Immunohistochemical studies confirmed the mixture of T cells (CD3þ) and macrophages (CD68þ) in foci of CV. The intensity of CD3 and CD68 stains correlated well with the severity of inflammation, with diffuse inflammation always associated with stronger CD3/CD68 staining compared to low-or high-grade inflammation, in both lean and obese placentas (Fig. 2) . Placental efficiency was measured by the ratio of fetal to placental weight; the entire cohort was normally distributed with a mean of 6.83 ± 1.27. Placental efficiency was decreased in the obese Table 4 Placental Histopathologic characteristics by maternal BMI and fetal sex. 
Discussion
This study confirms that maternal obesity is associated with placental overgrowth and fetal hypoxic stress as manifested by normoblastemia, the histopathologic correlates to prior studies reporting the association of maternal obesity with macrosomia and fetal distress [6, 7] . Likewise, placental efficiency, as measured by fetal to placental weight ratio, was decreased in obese women [10, 11] . The average increase in placental weight in our obese population (44 g) was similar to the increase in placental weight associated with multiparity (27e41 g); however, the latter finding was not significant when controlling for BMI.
Novel and more significant to our study was the association of maternal obesity with CV. It is well known that obesity is associated with inflammation, particularly macrophage infiltration, in other tissues and organs, including adipose tissue [14, 32] . We found both the prevalence, as well as the grade and extent, of CV to increase with increasing maternal BMI. CV was specifically associated with maternal pre-pregnancy BMI and not gestational weight gain. Although maternal diabetes and hypertension were positively associated with obesity in our study population, as expected [1, 3] , we found that CV was independent of these maternal comorbidities. Very few previous studies had investigated the association between maternal obesity and macrophage infiltration of the placenta, and these studies had shown mixed findings [18, 19] . One explanation for such mixed results is the small number of cases used; another may be the lack of consideration of fetal sex as a variable. In our study, CV was seen at a higher frequency in placentas of female fetuses, but only in the setting of maternal obesity. The pathophysiology of this finding is unclear and warrants further investigation. Interestingly, we also found an increased prevalence of fetal thrombosis in female placentas, not previously reported; this is likely secondary to the increased prevalence of CV in the same placentas, as fetal thrombosis-associated changes, such as avascular villi, can occur in the setting of villous inflammation [16] . However, fetal thrombosis was also increased in female placentas of lean women, who did not have an increased rate of CV.
An additional unexpected finding was the higher prevalence of patchy villous edema in male placentas. This lesion has been associated with fetal vascular malperfusion, and was also seen more commonly in preterm placentas, as previously reported [33] . Its higher prevalence in male placentas may therefore be a reflection of a higher proportion of male placentas amongst the preterm deliveries.
It is known that CV can be associated with fetal growth restriction, particularly when the associated lesion of fetal thrombosis is also present in the placenta [13,15e17] . As previously reported, placentas with CV were less likely to be large for gestational age. This finding was also seen in obese women, where CV was less commonly seen in large placentas. This could suggest that, in the setting of an otherwise destined-to-be-large placenta, villitis serves to normalize placental size. Given this, and the finding of increased risk of CV in female placentas of obese mothers, we expected a decreased risk of fetal macrosomia in female babies born to obese women; however, we did not see such a decrease. It is possible that given the rates of macrosomia in this study, we may not be adequately powered to see such an effect. The presence of CV also did not impact the duration of pregnancy or placental efficiency. It is therefore unclear as to what degree these variables (CV, fetal growth, and gestational age at delivery) are connected by the same pathophysiologic mechanism. Nevertheless, the possibility that CV serves to normalize placental size and may potentially also normalize birthweight is intriguing.
The largest previous study of placental pathology among obese women had shown an association of maternal obesity with maternal vascular lesions (decidual vasculopathy and atherosis), villous infarcts, fetal neutrophilic infiltration, and meconium staining of fetal membranes [11] . Among these four lesions, we only noted an association of maternal obesity with maternal vascular lesions; even there, multivariate analysis revealed these lesions to be related to maternal hypertensive disease. The different results are likely secondary to differences in the study populations. The above study used the Collaborative Perinatal Project data from a cohort of over 54,000 pregnancies delivering at 12 centers across the U.S., dating back to the 1960s. Also, the majority (59.3%) of the obese population is the CPP study was black [11] , compared to our mostly Hispanic obese population.
The strengths of this study are the large sample size, which permits stratification of the data. Likewise the amount of clinical data available for each case was robust and allowed the analyses to be controlled for potential confounders such as diabetes and hypertension. The evaluation of the placentas was uniform and performed by an expert in placental evaluation who was blinded to most clinical information, except for gestational age and indication for placental examination. Nevertheless, several limitations exist. Women delivering before 35 weeks were excluded due to the relatively small number in our cohort (<15); for this reason, the rate of preterm delivery in relation to maternal obesity is small. Also, we had very high rates of diabetes and hypertension among our patient population, typical of those seen at an academic tertiary care center; while efforts were made to control for these variables, our findings may not be fully generalizable to all populations. Finally, our numbers were not large enough to allow for evaluation of pregestational vs. gestational maternal disease, including hypertension and diabetes. Therefore, future studies should include larger cohorts in order to be better able to address the effect of multiple covariates simultaneously. Overall, our data underscore the importance of placental histopathology in evaluating effects of fetal sex and maternal obesity on pregnancy outcomes. This study was not designed to evaluate long-term outcomes, such as development of childhood obesity or diabetes. Future studies, including follow-up of the neonates in our series, could yield valuable information, specifically since it is now recognized that factors in utero can affect the health of the individual later in life. More research on the impact of maternal obesity, with consideration of placental pathology, is needed to address these questions.
